DK3242903T3 - Sammensætninger til at indføre nukleinsyre i celler - Google Patents
Sammensætninger til at indføre nukleinsyre i celler Download PDFInfo
- Publication number
- DK3242903T3 DK3242903T3 DK15823330.4T DK15823330T DK3242903T3 DK 3242903 T3 DK3242903 T3 DK 3242903T3 DK 15823330 T DK15823330 T DK 15823330T DK 3242903 T3 DK3242903 T3 DK 3242903T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- cells
- nucleic acid
- introducing nucleic
- introducing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199439.2A EP3034539A1 (en) | 2014-12-19 | 2014-12-19 | Compositions for introducing nucleic acid into cells |
| PCT/EP2015/080669 WO2016097377A1 (en) | 2014-12-19 | 2015-12-18 | Compositions for introducing nucleic acid into cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3242903T3 true DK3242903T3 (da) | 2021-09-27 |
Family
ID=52292658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15823330.4T DK3242903T3 (da) | 2014-12-19 | 2015-12-18 | Sammensætninger til at indføre nukleinsyre i celler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11020487B2 (enExample) |
| EP (2) | EP3034539A1 (enExample) |
| JP (1) | JP6745272B2 (enExample) |
| KR (1) | KR102142180B1 (enExample) |
| CN (1) | CN107001627B (enExample) |
| AU (1) | AU2015366220B2 (enExample) |
| BR (1) | BR112017012482B1 (enExample) |
| CA (1) | CA2971284C (enExample) |
| DK (1) | DK3242903T3 (enExample) |
| ES (1) | ES2887404T3 (enExample) |
| RU (1) | RU2715227C2 (enExample) |
| WO (1) | WO2016097377A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
| CA2990883A1 (en) | 2015-06-30 | 2017-01-05 | Ethris Gmbh | Atp-binding cassette family coding polyribonucleotides and formulations thereof |
| WO2018010815A1 (en) * | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| BR112020013974A8 (pt) * | 2018-01-11 | 2022-10-18 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Ggmbh | Formulação para administração de rna |
| JP7256824B2 (ja) | 2018-04-25 | 2023-04-12 | エスリス ゲーエムベーハー | 粒子状製剤用の凍結保護剤 |
| JP7863882B2 (ja) * | 2019-12-17 | 2026-05-22 | ウニヴェルズィテート ゲント | ポリプロピレンイミンを含む非ウイルスベクター |
| CN111249476B (zh) * | 2020-02-19 | 2023-09-26 | 深圳厚存纳米药业有限公司 | 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒 |
| MX2023009757A (es) | 2021-02-26 | 2023-09-04 | Ethris Gmbh | Formulaciones para la formacion de aerosoles y aerosoles para la administracion de acido nucleico. |
| WO2023049815A2 (en) * | 2021-09-22 | 2023-03-30 | Sirnaomics, Inc. | Improved nanoparticle formulations formed from histidine-lysine copolymers |
| CN118510549A (zh) * | 2021-09-22 | 2024-08-16 | 圣诺制药公司 | 具有减小的纳米颗粒尺寸和改善的多分散性指数的纳米颗粒药物组合物 |
| CN116549626A (zh) * | 2022-01-27 | 2023-08-08 | 深圳瑞吉生物科技有限公司 | 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用 |
| EP4327829A1 (en) | 2022-08-26 | 2024-02-28 | Ethris GmbH | Stabilization of lipid or lipidoid nanoparticle suspensions |
| EP4577243A1 (en) | 2022-08-26 | 2025-07-02 | Ethris GmbH | Stable lipid or lipidoid nanoparticle suspensions |
| WO2024240962A1 (en) | 2023-05-25 | 2024-11-28 | Ethris Gmbh | Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof |
| CN116478410B (zh) * | 2023-06-20 | 2023-09-12 | 觅投克(北京)生物医学技术有限公司 | 一种菊糖修饰的聚乙烯亚胺衍生物及其制备方法和应用 |
| CN121729225A (zh) | 2023-08-25 | 2026-03-24 | 埃泽瑞斯公司 | 具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂 |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| FR3155424A1 (fr) | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026082899A2 (en) | 2024-10-16 | 2026-04-23 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2026119817A1 (en) | 2024-12-02 | 2026-06-11 | BioNTech SE | Agents and methods for targeted delivery of immune effector cells |
| WO2026125590A1 (en) | 2024-12-13 | 2026-06-18 | BioNTech SE | Measuring nucleic acid integrity |
| WO2026125598A1 (en) | 2024-12-13 | 2026-06-18 | BioNTech SE | Measuring nucleic acid integrity |
| WO2026148356A1 (en) | 2025-01-06 | 2026-07-09 | BioNTech SE | Coronavirus and influenza immunogenic combinations |
| WO2026150132A1 (en) | 2025-01-12 | 2026-07-16 | BioNTech SE | Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment |
| WO2026162682A1 (en) | 2025-01-29 | 2026-08-06 | BioNTech SE | Compositions for delivery of plasmodium rh5 antigens and related methods |
| WO2026162552A1 (en) | 2025-01-31 | 2026-08-06 | BioNTech SE | Agents and methods for targeted delivery to cells |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| JPS5821590A (ja) | 1981-07-31 | 1983-02-08 | 株式会社東芝 | 制御棒駆動水圧装置 |
| JPS58215490A (ja) * | 1982-06-08 | 1983-12-14 | Nippon Shokubai Kagaku Kogyo Co Ltd | 石炭−水スラリ−用分散剤 |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
| DE19527102A1 (de) * | 1995-07-25 | 1997-01-30 | Bayer Ag | Neue Polyamine und ihre Verwendung in Lacken und Beschichtungen |
| US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
| FR2739292B1 (fr) * | 1995-09-28 | 1997-10-31 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations |
| JP2003526692A (ja) * | 1997-08-01 | 2003-09-09 | サプラテック ファーマ インコーポレーテッド | ポリヌクレオチド組成物 |
| WO2001000708A1 (de) | 1999-06-25 | 2001-01-04 | Christian Plank | Kombinationen zur einführung von nucleinsäuren in zellen |
| DE19933024C2 (de) | 1999-07-15 | 2003-03-13 | Medinnova Ges Med Innovationen | Kationische Blockcopolymere |
| WO2002000870A2 (en) | 2000-06-26 | 2002-01-03 | Christian Plank | Method for transfecting cells using a magnetic field |
| US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| US20070269891A9 (en) | 2003-01-13 | 2007-11-22 | Yasunobu Tanaka | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
| JP4535229B2 (ja) | 2003-05-08 | 2010-09-01 | 国立大学法人 東京大学 | ポリエチレングリコール−ポリカチオンブロック共重合体 |
| WO2006085664A1 (ja) | 2005-02-10 | 2006-08-17 | The University Of Tokyo | ポリカチオン荷電性ポリマー及び核酸のキャリヤーとしての使用 |
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| KR101388320B1 (ko) | 2005-12-15 | 2014-04-22 | 뽈리쁠뤼스-트랑스펙씨옹 | 양이온성 올리고뉴클레오티드, 이를 제조하기 위한 자동화방법 및 이의 용도 |
| US7700541B2 (en) | 2006-04-06 | 2010-04-20 | Nitto Denko Corporation | Biodegradable cationic polymers |
| GB0613753D0 (en) * | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
| CN101500548A (zh) * | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| US20090042825A1 (en) * | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| EP2271699A1 (en) * | 2008-03-14 | 2011-01-12 | Egen, Inc. | Biodegradable cross-linked branched poly (alkylene imines) |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| WO2010065660A2 (en) | 2008-12-02 | 2010-06-10 | University Of Utah Research Foundation | Biodegradable polydisulfide amines for gene delivery |
| EA022786B1 (ru) | 2009-07-31 | 2016-03-31 | Этрис Гмбх | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков |
| WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| US9931418B2 (en) | 2012-08-07 | 2018-04-03 | Northeastern University | Compositions for the delivery of RNA and drugs into cells |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
-
2014
- 2014-12-19 EP EP14199439.2A patent/EP3034539A1/en not_active Withdrawn
-
2015
- 2015-12-18 EP EP15823330.4A patent/EP3242903B1/en active Active
- 2015-12-18 ES ES15823330T patent/ES2887404T3/es active Active
- 2015-12-18 AU AU2015366220A patent/AU2015366220B2/en not_active Ceased
- 2015-12-18 RU RU2017122022A patent/RU2715227C2/ru active
- 2015-12-18 CA CA2971284A patent/CA2971284C/en active Active
- 2015-12-18 WO PCT/EP2015/080669 patent/WO2016097377A1/en not_active Ceased
- 2015-12-18 KR KR1020177019543A patent/KR102142180B1/ko active Active
- 2015-12-18 DK DK15823330.4T patent/DK3242903T3/da active
- 2015-12-18 BR BR112017012482-3A patent/BR112017012482B1/pt active IP Right Grant
- 2015-12-18 CN CN201580068845.7A patent/CN107001627B/zh active Active
- 2015-12-18 JP JP2017533008A patent/JP6745272B2/ja active Active
- 2015-12-18 US US15/537,096 patent/US11020487B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3242903B1 (en) | 2021-07-28 |
| US20180236090A1 (en) | 2018-08-23 |
| KR102142180B1 (ko) | 2020-08-07 |
| BR112017012482B1 (pt) | 2021-10-19 |
| RU2715227C2 (ru) | 2020-02-26 |
| WO2016097377A1 (en) | 2016-06-23 |
| JP2018502956A (ja) | 2018-02-01 |
| RU2017122022A3 (enExample) | 2019-05-22 |
| ES2887404T3 (es) | 2021-12-22 |
| KR20170097124A (ko) | 2017-08-25 |
| CN107001627B (zh) | 2020-01-14 |
| JP6745272B2 (ja) | 2020-08-26 |
| BR112017012482A2 (pt) | 2018-02-27 |
| RU2017122022A (ru) | 2018-12-24 |
| EP3242903A1 (en) | 2017-11-15 |
| US11020487B2 (en) | 2021-06-01 |
| CA2971284C (en) | 2023-01-10 |
| EP3034539A1 (en) | 2016-06-22 |
| AU2015366220A1 (en) | 2017-06-01 |
| CN107001627A (zh) | 2017-08-01 |
| AU2015366220B2 (en) | 2019-09-19 |
| CA2971284A1 (en) | 2016-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901336B (en) | Improved t cell compositions | |
| IL254000B (en) | Nucleic acid sequence assembly | |
| IL252556A0 (en) | Nucleic acid constructs for genome editing | |
| SI3294325T1 (sl) | Krepitev učinka car-izdelanih t celic s cepljenjem z nukleinsko kislino | |
| SG10201912283RA (en) | Nucleic acid sequence analysis from single cells | |
| LT3334841T (lt) | Nukleorūgščių tyrimo būdai | |
| DK3129487T3 (da) | Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression | |
| PL3118311T3 (pl) | Antysensowny kwas nukleinowy | |
| LT3229959T (lt) | Didelio efektyvumo nukleorūgščių sintezė mažame tūryje | |
| HUE046262T2 (hu) | Sejt | |
| IL253464B (en) | Universal killer t-cell | |
| DK3394248T3 (da) | Dendritisk cellesammensætning | |
| HUE043599T2 (hu) | Nem-vizes elektrolit kompozíciók | |
| LT3157504T (lt) | Kamienines ląsteles stimuliuojančios kompozicijos | |
| PT3291821T (pt) | Imunoterapêutica com células dendríticas | |
| DK3365107T3 (da) | Cellekultur | |
| KR102535561B9 (ko) | 태양 전지를 이용한 구조물 | |
| IL266111A (en) | Methods for inducing a t-cell response | |
| DK3253906T3 (da) | Elektrolyt til elektroplettering | |
| IL260122A (en) | Methods and compositions for assembly of nucleic acids | |
| DK3663407T3 (da) | Fremgangsmåde til nukleinsyresekvensering | |
| DE102016111219A8 (de) | Brennstoffzellensystem | |
| FI20150044A7 (fi) | Rasvahappokoostumus | |
| JP2016096066A5 (ja) | 燃料電池システム | |
| HUE042287T2 (hu) | Lítium-kén cella |